Madrigal Pharmaceuticals, Inc. — 2022 Form 10-K Summary
Business context and reporting period
For the fiscal year ended December 31, 2022, Madrigal was a clinical-stage biopharmaceutical company with no product revenue. Its principal asset was resmetirom, an oral, liver-directed thyroid hormone receptor-β agonist in development for nonalcoholic steatohepatitis (NASH). The filing reports full-year results and unaudited fourth-quarter data; it is not a standalone quarterly filing.
Financial and operating results
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $245.4 million | $205.2 million |
| General and administrative expense | $48.1 million | $37.3 million |
| Total operating expenses | $293.6 million | $242.5 million |
| Net loss | $295.4 million | $241.8 million |
| Basic and diluted net loss per share | $17.23 | $14.63 |
| Net cash used in operating activities | $224.9 million | $183.9 million |
For Q4 2022, revenue was $0; operating expenses were $85.3 million and net loss was $85.9 million, versus $64.6 million and $64.5 million, respectively, in Q4 2021. Q4 2022 R&D expense was $70.7 million and G&A expense was $14.6 million.
At December 31, 2022, cash and cash equivalents were $331.5 million and marketable securities were $27.2 million, totaling $358.8 million. Current assets were $361.4 million and current liabilities $115.9 million. The company reported $50.0 million of loan principal outstanding (carrying value, net of discount, $49.3 million); the stated interest rate at year-end was 11.45%. No operating margin is meaningful because the company had no revenue.
Cash flow included $206.7 million provided by investing activities, principally net sales and maturities of marketable securities, and $313.5 million provided by financing activities, including equity proceeds and the initial $50.0 million loan draw. The company raised approximately $155.9 million net under its ATM program and $99.5 million net in a December registered offering. Accumulated deficit was $962.7 million.
Material changes and notable developments
- Annual net loss increased 22% year over year as operating expenses grew 21%. Management attributed higher R&D costs mainly to Phase 3 trial activity, headcount and stock compensation; G&A rose with commercialization preparation, headcount and stock compensation.
- In December 2022, Madrigal reported topline results from the pivotal MAESTRO-NASH Phase 3 biopsy study. At 52 weeks, resmetirom 80 mg and 100 mg achieved both primary endpoints versus placebo: NASH resolution was 26% and 30%, respectively, versus 10%; fibrosis improvement was 24% and 26%, versus 14%.
- At 24 weeks, LDL-C declined 12% with 80 mg and 16% with 100 mg, versus a 1% increase with placebo. These were topline findings; patients remain in follow-up for clinical outcomes.
- In January 2022, Madrigal reported that the MAESTRO-NAFLD-1 safety study met its primary and key secondary endpoints, including reductions in liver fat and atherogenic lipids. In August 2022, it initiated MAESTRO-NASH-OUTCOMES, a study planned to enroll approximately 700 patients with compensated NASH cirrhosis.
Outlook, risks and contingencies
Management expected R&D spending to increase as development advanced and G&A spending to rise with commercialization preparations. It stated that year-end cash, cash equivalents and marketable securities were expected to fund operations for more than one year from issuance of the financial statements, while also noting that substantial future capital would be needed for longer-term development and commercialization. Additional financing may not be available on acceptable terms.
Resmetirom had not received regulatory approval for any indication at the filing date. Potential accelerated approval based on surrogate endpoints remained subject to FDA review; confirmatory outcomes studies and further regulatory requirements could affect timing or approval. The filing highlights clinical efficacy and long-term safety uncertainty, trial and enrollment execution, manufacturing dependence (including a single source for API and finished product at the time), competition, reimbursement and pricing, intellectual-property protection, and commercialization capability as key risks.
The May 2022 Hercules loan facility provided for up to $250 million subject to conditions and milestones. It is secured by substantially all company assets other than intellectual property and includes financial and other restrictive covenants, including a $35 million minimum-cash covenant. In February 2023, after year-end, the company drew an additional $35 million under amended Tranche 2; the amendment also changed the interest-rate terms. These subsequent events are not included in the December 31, 2022 balance sheet.
The company reported no material legal proceedings, no off-balance-sheet arrangements, and no cash dividends. The auditor gave an unmodified opinion on the financial statements and internal control over financial reporting; the audit report included an emphasis of matter that additional financing would be required. Management and the auditor reported effective internal controls as of year-end.
Important facts for investors to verify
- FDA submission and review status, any requested additional data, and the requirements and timing for potential accelerated or full approval.
- Full MAESTRO-NASH data, including endpoint analyses, safety and discontinuation details, and longer-term clinical outcomes.
- Cash runway under the current spending plan, forecast cash burn, and financing needs, including actual availability and covenant terms of remaining loan tranches.
- Commercial launch readiness, manufacturing capacity and second-source development, potential pricing and reimbursement, and ex-U.S. partnering plans.
- Potential dilution from equity or preferred securities, options and warrants, as well as the effect of debt covenants and required repayments.